MedTrace Logo

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

NCT06008691 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-12-29

No results posted yet for this study

Summary

This is a prospective, observational cohort study to evaluate the clinical impact of novel Monoclonal AntiBodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice.

Conditions

  • Non-Hodgkin Lymphoma, B-cell

Interventions

DRUG

"novel" MAB (alone or in combination)

"novel" MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Marco Ladetto, Prof. · AO SS Antonio e Biagio e Cesare Arrigo, Alessandria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2038-10-31
Completion
2038-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008691 on ClinicalTrials.gov